Overview
WGS market data
Price History
WGS price chart · 1M
- O
- 85.98
- H
- 90.54
- L
- 85.65
- C
- 90.26
- Vol
- 24,369.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $85.98
- Previous Close
- $87.40
- Day High
- $90.54
- Day Low
- $85.65
- 52 Week High
- $95.28
- 52 Week Low
- $32.33
- 7 Day Return
- +13.27%
- 30 Day Return
- +48.98%
- 90 Day Return
- +80.47%
- 1 Year Return
- +2.40%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.73 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -23.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $32.21 – $170.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.4B · P/B 12.20 · P/S 5.38.
Company News
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List InsideBenzinga · Aug 26, 2026, 2:57 PM
GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric CareBenzinga · Aug 24, 2026, 1:28 PM
GeneDx Holdings shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Canaccord Genuity raised its price target from $75 to $90.Benzinga · Aug 4, 2026, 12:27 PM
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90Benzinga · Aug 4, 2026, 12:21 PM
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price TargetBenzinga · Aug 4, 2026, 9:15 AM
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M EstimateBenzinga · Aug 3, 2026, 9:31 PM
GeneDX Holdings shares are trading lower after the company reported mixed Q2 financial results.Benzinga · Aug 3, 2026, 8:35 PM
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M EstBenzinga · Aug 3, 2026, 8:19 PM
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M EstimateBenzinga · Aug 3, 2026, 8:09 PM
GENEDX HOLDINGS DEADLINE AUGUST 3rd: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the FirmGlobenewswire Inc · Jul 27, 2026, 11:15 PM